Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed the day trading at $6.10 down -1.21% from the previous closing price of $6.18. In other words, the price has decreased by -$1.21 from its previous closing price. On the day, 10.4 million shares were traded. RXRX stock price reached its highest trading level at $6.26 during the session, while it also had its lowest trading level at $5.9.
Ratios:
For a better understanding of RXRX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.35 and its Current Ratio is at 4.35. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 13 ’24 when Gibson Christopher sold 20,000 shares for $7.74 per share. The transaction valued at 154,800 led to the insider holds 762,656 shares of the business.
Gibson Christopher sold 20,000 shares of RXRX for $147,000 on Nov 14 ’24. The Chief Executive Officer now owns 762,656 shares after completing the transaction at $7.35 per share. On Nov 12 ’24, another insider, Borgeson Blake, who serves as the Director of the company, sold 11,447 shares for $7.64 each. As a result, the insider received 87,457 and left with 7,066,113 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 1748510080 and an Enterprise Value of 1434204160. For the stock, the TTM Price-to-Sale (P/S) ratio is 23.97 while its Price-to-Book (P/B) ratio in mrq is 3.32. Its current Enterprise Value per Revenue stands at 22.002 whereas that against EBITDA is -3.938.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $15.74, while it has fallen to a 52-week low of $5.89. The 50-Day Moving Average of the stock is -8.38%, while the 200-Day Moving Average is calculated to be -27.16%.
Shares Statistics:
Over the past 3-months, RXRX traded about 5.03M shares per day on average, while over the past 10 days, RXRX traded about 7416730 shares per day. A total of 226.26M shares are outstanding, with a floating share count of 221.54M. Insiders hold about 22.71% of the company’s shares, while institutions hold 79.05% stake in the company. Shares short for RXRX as of 1730332800 were 62427631 with a Short Ratio of 12.41, compared to 1727654400 on 62578756. Therefore, it implies a Short% of Shares Outstanding of 62427631 and a Short% of Float of 24.560000000000002.
